IP Library › Granted Patent US 12686706
Granted Patent B2
US 12686706 · App. 17/784,591 · Granted Jul 21, 2026

Compound and method for treatment of alzheimer's disease

Inventor: Jan Johansson (Stockholm, SE)
Assignee: ALPHABETA AB
C07K14/47A61P25/28A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12686706
App. No.
17/784,591
Granted
Jul 21, 2026
Kind
B2
Abstract

An isolated protein comprising a moiety of 90-200 amino acid residues having at least 70% identity to Bri2 BRICHOS, wherein the amino acid residue corresponding to Arg in position 221 in full-length Bri2 wt is not Arg, Lys or His. The protein is useful as a medicament for use in treatment of Alzheimer's Disease.

Claims (10)

1 . An isolated protein comprising a moiety of 90-200 amino acid residues having at least 70% identity to SEQ ID NO: 7, wherein the amino acid residue corresponding to position 221 in SEQ ID NO: 1 is selected from the group consisting of Glu and Asp.

2 . The isolated protein according to claim 1 , wherein the amino acid residue corresponding to position 221 in SEQ ID NO: 1 is Glu.

3 . The isolated protein according to claim 1 , wherein the moiety has at least 80% identity to SEQ ID NO: 7.

4 . The isolated protein according to claim 1 , consisting of not more than 500 amino acid residues.

5 . The isolated protein according to claim 1 , which has the amino acid sequence of SEQ ID NO: 4 or the amino acid sequence of SEQ ID NO: 13.

6 . The isolated protein according to claim 1 , wherein the moiety has at least 90% identity to SEQ ID NO: 7.

7 . The isolated protein according to claim 1 , wherein the moiety has at least 95% identity to SEQ ID NO: 7.

8 . The isolated protein according to claim 1 , wherein the moiety comprises the amino acid sequence of SEQ ID NO: 7, with the exception that the amino acid residue corresponding to position 221 in SEQ ID NO: 1 is selected from the group consisting of Glu and Asp.

9 . A pharmaceutical composition comprising a therapeutically effective amount of the isolated protein according to claim 1 and a pharmaceutical carrier.

10 . A nucleic acid comprising a sequence encoding the isolated protein according to claim 1 .